MINNEAPOLIS, July 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2024 after the close of trading on Tuesday, August 6. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 202 ...

MINNEAPOLIS, July 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2024 after the close of trading on Tuesday, August 6. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 202 ...

文章核心观点 - Inspire Medical Systems, Inc.在未来几个季度有望实现增长,这得益于其在研发方面的重点投入[1][3] - 公司一季度业绩表现出色,以及其全球业务布局有望进一步推动增长[5][7] - 但公司过度依赖Inspire系统,以及面临激烈的竞争格局仍是需要关注的问题[9][11] 公司表现 - 公司一季度业绩表现出色,收入和利润均有大幅改善,毛利率也有所提升[5] - 公司致力于研发创新,持续投入现有和新一代技术,以改善产品和临床效果,提高患者接受度和舒适度,扩大受益人群[6] - 公司正计划继续扩大直销团队规模和地域覆盖,以推动未来收入增长[7] - 公司在本季度新增66家美国医疗中心提供Inspire疗法,并新增11个销售区域[8] 行业竞争 - 公司销售收入主要来自Inspire系统,其增长战略和盈利能力很大程度上依赖于Inspire疗法在中重度阻塞性睡眠呼吸暂停患者中的市场接受度[9][10] - 医疗技术行业竞争激烈,公司面临来自其他神经刺激技术的竞争[11]

Inspire Medical Systems, Inc. (INSP) delivered a loss per share of 34 cents in first-quarter 2024, narrower than the year-ago period’s loss of 53 cents per share. The metric was also narrower than the Zacks Consensus Estimate of a loss of 63 cents per share. Revenues in Detail Inspire Medical registered revenues of $164 million in the first quarter, up 28.2% year over year. The figure beat the Zacks Consensus Estimate by 1.5%. Per management, the top-line growth was driven by increased market penetration in ...

For the quarter ended March 2024, Inspire Medical Systems (INSP) reported revenue of $164.01 million, up 28.2% over the same period last year. EPS came in at -$0.34, compared to -$0.53 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $161.63 million, representing a surprise of +1.47%. The company delivered an EPS surprise of +46.03%, with the consensus EPS estimate being -$0.63. While investors scrutinize revenue and earnings changes year-over-year and how they compa ...

财务数据和关键指标变化 - 公司第一季度收入为1.64亿美元,同比增长28% [1][2] - 美国收入为1.558亿美元,同比增长25% [2] - 海外收入为8.2百万美元,同比增长141% [2] - 毛利率为84.9%,同比提升0.5个百分点 [3] - 净亏损为1000万美元,同比减少5.4百万美元 [3] - 每股亏损为0.34美元,同比减少0.19美元 [3] - 公司预计2024年全年收入将达到7.83-7.93亿美元,同比增长25%-27% [2][3] - 公司预计2024年将实现盈利,每股收益为0.10-0.20美元 [3] 各条业务线数据和关键指标变化 - 美国业务收入增长25%,主要得益于现有中心的渗透率提升以及新中心的开设 [2] - 海外业务收入增长141%,主要得益于德国市场的强劲反弹 [2] 各个市场数据和关键指标变化 - 美国市场收入增长25%,主要得益于现有中心的渗透率提升以及新中心的开设 [2] - 欧洲市场收入大幅增长141%,主要得益于德国市场的强劲反弹 [2] 公司战略和发展方向及行业竞争 - 公司计划在2024年内开设52-56家新的美国中心,并建立12-14个新的销售区域 [3] - 公司将从2025年开始报告收入增长和每股收益,不再提供中心和销售区域的具体数据 [3][4] - 公司认为GLP-1药物可能与Inspire治疗产生协同效应,有助于提高高BMI患者的治疗资格 [2][5] - 公司正在开展PREDICTOR研究,旨在开发一种新的方法替代睡眠内窥镜检查,为部分患者简化诊断流程 [2][6] 管理层对经营环境和未来前景的评论 - 公司对2024年剩余时间以及未来的业务发展保持信心,预计将实现全年盈利 [3] - 公司认为GLP-1药物可能与Inspire治疗产生协同效应,有助于提高高BMI患者的治疗资格 [2][5] - 公司正在开展PREDICTOR研究,旨在开发一种新的方法替代睡眠内窥镜检查,为部分患者简化诊断流程 [2][6] 问答环节重要的提问和回答 问题1 **Danielle Antalffy 提问** 询问美国业务一季度增长25%低于预期的原因,以及私付险政策变化的影响 [1] **Tim Herbert 回答** 公司预期一季度存在较强的季节性,团队控制住了15%的季节性波动,美国业务保持强劲增长。公司密切关注私付险政策变化,目前尚未发现对业务产生重大影响 [1] 问题2 **Travis Steed 提问** 询问美国中心使用率放缓的原因,以及不再报告中心和销售区域数据的原因 [4] **Tim Herbert 回答** 中心使用率持续是公司关注重点,一季度使用率与去年同期基本持平。公司随着业务发展将更多关注收入和利润指标,不再单独报告中心和销售区域数据 [4] 问题3 **Adam Maeder 提问** 询问收入指引上调的原因,是否主要来自于海外业务 [2][3] **Rick Buchholz 回答** 收入指引上调主要体现在下半年,来自于美国和海外业务的共同贡献。公司预计海外业务将持续保持良好增长势头 [2][3]

Inspire Medical Systems (INSP) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 46.03%. A quarter ago, it was expected that this maker of devices for treating obstructive sleep apnea would post a loss of $0.04 per share when it actually produced earnings of $0.49, delivering a surprise of 1,3 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q ________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 ______________________________ Inspire ...

Exhibit 99.1 Inspire Medical Systems, Inc. Announces First Quarter 2024 Financial Results and Updates 2024 Outlook Inspire Reports Year-over-Year Revenue Growth of 28% in the First Quarter and Expects Profitability for the Full Year 2024 MINNEAPOLIS, Minnesota - May 7, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported f ...

Inspire Reports Year-over-Year Revenue Growth of 28% in the First Quarter and Expects Profitability for the Full Year 2024 MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2024. Recent Business Highlights Generated revenue of $164.0 ...